Multifunctional antioxidant activity of HBED iron chelator

被引:31
作者
Samuni, AM [1 ]
Afeworki, M [1 ]
Stein, W [1 ]
Yordanov, AT [1 ]
DeGraff, W [1 ]
Krishna, MC [1 ]
Mitchell, JB [1 ]
Brechbiel, MW [1 ]
机构
[1] NCI, Radiat Biol Branch, Div Clin Sci, NIH, Bethesda, MD 20892 USA
关键词
free radicals; redox-activity; oxidative damage; antioxidant; iron chelator; metal ions; cytoprotection; H-donation;
D O I
10.1016/S0891-5849(00)00459-7
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The use of N,N'-bis (2-hydroxybenzyl) ethylenediamine-N,N'-diacetic acid (HBED) for iron chelation therapy is currently being tested. Besides its affinity for iron, bioavailability, and efficacy in relieving iron overload, it is important to assess its anti- and/or pro-oxidant activity. To address these questions, the antioxidant/pro-oxidant effects of HEED in a cell-free solution and on cultured Chinese hamster V79 cells were studied using UV-VIS spectrophotometry, oximetry, spin trapping, and electron paramagnetic resonance (EPR) spectrometry. The results indicate that HEED facilitates Fe(II) oxidation but blocks O-2(.-)-induced reduction of Fe(III) and consequently pre-empts production of (OH)-O-. or hypervalent iron through the Haber-Weiss reaction cycle. The efficacy of HEED as a 1-electron donor (H-donation) was demonstrated by reduction of the 2,2'-azino-bis(3-ethylbenzothiazoline-6-sulfonate)-derived nitrogen-centered radical cation (ABTS(.+)), accompanied by formation of a short-lived phenoxyl radical. HEED also provided cytoprotection against toxicity of H2O2 and t-BuOOH. Our results show that HEED can act both as a H-donating antioxidant and as an effective chelator lacking pro-oxidant capacity, thus substantiating its promising use in iron chelation therapy. (C) 2001 Elsevier Science Inc.
引用
收藏
页码:170 / 177
页数:8
相关论文
共 29 条
[1]  
BERGERON RJ, 1993, BLOOD, V81, P2166
[2]  
BERGERON RJ, 1992, BLOOD, V79, P1882
[3]   HBED: A potential alternative to deferoxamine for iron-chelating therapy [J].
Bergeron, RJ ;
Wiegand, J ;
Brittenham, GM .
BLOOD, 1998, 91 (04) :1446-1452
[4]   HBED: The continuing development of a potential alternative to deferoxamine for iron-chelating therapy [J].
Bergeron, RJ ;
Wiegand, J ;
Brittenham, GM .
BLOOD, 1999, 93 (01) :370-375
[5]   Desazadesmethyldesferrithiocin analogues as orally effective iron chelators [J].
Bergeron, RJ ;
Wiegand, J ;
Weimar, WR ;
Vinson, JRT ;
Bussenius, J ;
Yao, GW ;
McManis, JS .
JOURNAL OF MEDICINAL CHEMISTRY, 1999, 42 (01) :95-108
[6]   EFFICACY OF DEFEROXAMINE IN PREVENTING COMPLICATIONS OF IRON OVERLOAD IN PATIENTS WITH THALASSEMIA MAJOR [J].
BRITTENHAM, GM ;
GRIFFITH, PM ;
NIENHUIS, AW ;
MCLAREN, CE ;
YOUNG, NS ;
TUCKER, EE ;
ALLEN, CJ ;
FARRELL, DE ;
HARRIS, JW .
NEW ENGLAND JOURNAL OF MEDICINE, 1994, 331 (09) :567-573
[7]   MODEL STUDIES OF THE IRON-CATALYZED HABER-WEISS CYCLE AND THE ASCORBATE-DRIVEN FENTON REACTION [J].
BURKITT, MJ ;
GILBERT, BC .
FREE RADICAL RESEARCH COMMUNICATIONS, 1990, 10 (4-5) :265-280
[8]   VIABILITY MEASUREMENTS IN MAMMALIAN-CELL SYSTEMS [J].
COOK, JA ;
MITCHELL, JB .
ANALYTICAL BIOCHEMISTRY, 1989, 179 (01) :1-7
[9]   THE ACTION OF 9 CHELATORS ON IRON-DEPENDENT RADICAL DAMAGE [J].
DEAN, RT ;
NICHOLSON, P .
FREE RADICAL RESEARCH, 1994, 20 (02) :83-101
[10]   CATALYSIS OF THE HABER-WEISS REACTION BY IRON-DIETHYLENETRIAMINEPENTAACETATE [J].
EGAN, TJ ;
BARTHAKUR, SR ;
AISEN, P .
JOURNAL OF INORGANIC BIOCHEMISTRY, 1992, 48 (04) :241-249